Tazemetostat Brand names: Tazverik

What is tazemetostat used for?

From the label: indications and usage

TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. […]

Conditions named in the indications of tazemetostat's FDA labels, with every medicine labeled for each:

• Leukemia, lymphoma and myeloma

From other tazemetostat labels

Leukemia, lymphoma and myeloma: Relapsed or Refractory Follicular Lymphoma TAZVERIK is indicated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved …

FDA pharmacologic class: Methyltransferase Inhibitor.

What does the patient leaflet for tazemetostat say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about TAZVERIK?

TAZVERIK can cause serious side effects, including: Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness. See " What are the possible side effects of TAZVERIK " for more information about side effects. What is TAZVERIK? TAZVERIK is a prescription medicine used to treat: adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery. adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you. adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options. It is not known if TAZVERIK is safe and effective in children less than 16 years of age. Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. […]

From the patient leaflet: What should I avoid while taking TAZVERIK?

Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK. Avoid taking St. John's wort during treatment with TAZVERIK.

From the patient leaflet: How should I store TAZVERIK?

Do not store TAZVERIK tablets above 86°F (30°C). Keep TAZVERIK and all medicines out of the reach of children.

Is there a generic for tazemetostat (Tazverik)?

No generic tazemetostat is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 27 patents for Tazverik tablets: the compound patent runs to January 23, 2034, and the last listed entry to May 3, 2038. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

Is tazemetostat in shortage?

No tazemetostat presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated March 27, 2026. ASHP keeps a separate shortage list, which can differ.

Every tazemetostat presentation in the FDA shortage database

What do FAERS reports show for tazemetostat?

The FDA Adverse Event Reporting System holds 1,598 reports that list tazemetostat among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 209 are coded as a death and 322 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

• 0
• 3
• 11
• 6
• 81
• 256
• 395
• 316
• 205
• 242
• 83

• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

The most reported reactions

• Off Label Use (a use or a product term, not a reaction)334
• Fatigue (named in the label)326
• Disease Progression (a use or a product term, not a reaction)305
• Nausea (named in the label)235
• Product Dose Omission Issue (a use or a product term, not a reaction)212
• Death (an outcome recorded in the report)125
• Diarrhoea (named in the label)122
• Decreased Appetite (named in the label)97

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as tazemetostat?

37 other medicines are given the same way (oral) and in the same FDA class as tazemetostat or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

What next?

Tazemetostat side effects

the label's list beside FAERS reports

Tazemetostat shortage record

every presentation, company and date

Check an interaction

what two or more labels say about each other